Stoke Therapeutics, Inc. (STOK)Healthcare | Biotechnology | Bedford, United States | NasdaqGS
22.70 USD
+0.20
(0.889%)
⇧
(Oct. 14, 2026, 12:21 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 4:03 a.m. EDT
Despite a 'strong buy' analyst consensus driven by the potential of its Dravet syndrome lead asset, the market is pricing in significant near-term risk. The stock has suffered a brutal multi-year decline, dropping nearly 65% last year and halving the year prior, leaving it far below its 2020 highs. Fundamentals remain precarious with negative earnings, shrinking revenue, and heavy cash burn, meaning the company relies entirely on capital markets to survive. The options data confirms this fear, with traders aggressively buying puts to cap losses rather than betting on an immediate recovery. While the long-term thesis on the drug could be transformative, the current balance sheet and recent price action suggest the stock is in a survival mode where downside risk outweighs the probability of a quick rebound. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.068627 |
| AutoETS | 0.068627 |
| MSTL | 0.069365 |
| AutoTheta | 0.080746 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 1.39 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.088 |
| Excess Kurtosis | -0.22 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.776 |
| Revenue per Share | 0.442 |
| Market Cap | 1,464,745,728 |
| Forward P/E | -6.43 |
| Beta | 1.26 |
| Website | https://www.stoketherapeutics.com |
As of Oct. 10, 2026, 4:03 a.m. EDT: Speculators are positioning heavily for downside protection, evidenced by massive put volume and open interest at strikes like $22.50 and $30.00, particularly expiring in November 2026. While there is some call activity at higher strikes ($40), the overwhelming sentiment is hedging against a drop, with put open interest significantly outweighing call open interest at key defensive levels.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.3679775 |
| Address1 | 45 Wiggins Avenue |
| All Time High | 71.58 |
| All Time Low | 3.35 |
| Ask | 28.71 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 921,960 |
| Average Daily Volume3 Month | 857,543 |
| Average Volume | 857,543 |
| Average Volume10Days | 921,960 |
| Beta | 1.262 |
| Bid | 17.18 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 5.537 |
| City | Bedford |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 22.7 |
| Current Ratio | 7.692 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 23.03 |
| Day Low | 22.05 |
| Debt To Equity | 0.776 |
| Display Name | Stoke Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,787,200 |
| Earnings Call Timestamp Start | 1,785,787,200 |
| Earnings Timestamp | 1,785,787,200 |
| Earnings Timestamp End | 1,793,736,000 |
| Earnings Timestamp Start | 1,793,736,000 |
| Ebitda | -221,632,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -5.242 |
| Enterprise To Revenue | 42.109 |
| Enterprise Value | 1,161,704,448 |
| Eps Current Year | -3.62068 |
| Eps Forward | -3.52762 |
| Eps Trailing Twelve Months | -3.38 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 29.1716 |
| Fifty Day Average Change | -6.4715996 |
| Fifty Day Average Change Percent | -0.2218459 |
| Fifty Two Week Change Percent | -36.79775 |
| Fifty Two Week High | 40.22 |
| Fifty Two Week High Change | -17.52 |
| Fifty Two Week High Change Percent | -0.43560418 |
| Fifty Two Week Low | 20.32 |
| Fifty Two Week Low Change | 2.380001 |
| Fifty Two Week Low Change Percent | 0.11712604 |
| Fifty Two Week Range | 20.32 - 40.22 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,560,951,000,000 |
| Float Shares | 45,614,246 |
| Forward Eps | -3.52762 |
| Forward P E | -6.4349337 |
| Free Cashflow | -106,202,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 170 |
| Fullday Change | 0.20000076 |
| Fullday Change Percent | 0.8888923 |
| Fullday Price | 22.7 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 1.0 |
| Gross Profits | 27,588,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03683 |
| Held Percent Institutions | 1.2533699 |
| Implied Shares Outstanding | 64,526,242 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. |
| Long Name | Stoke Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 1,464,745,728 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_251758622 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -207,903,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,682,199,128 |
| Number Of Analyst Opinions | 13 |
| Open | 22.43 |
| Operating Cashflow | -177,987,008 |
| Operating Margins | -7.01651 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 781 430 8200 |
| Previous Close | 22.5 |
| Price Eps Current Year | -6.269541 |
| Price Hint | 2 |
| Price To Book | 4.099693 |
| Price To Sales Trailing12 Months | 53.093582 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.191 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.14286 |
| Region | US |
| Regular Market Change | 0.20000076 |
| Regular Market Change Percent | 0.8888923 |
| Regular Market Day High | 23.03 |
| Regular Market Day Low | 22.05 |
| Regular Market Day Range | 22.05 - 23.03 |
| Regular Market Open | 22.43 |
| Regular Market Previous Close | 22.5 |
| Regular Market Price | 22.7 |
| Regular Market Time | 1,791,994,883 |
| Regular Market Volume | 462,285 |
| Return On Assets | -0.35868 |
| Return On Equity | -0.61104 |
| Revenue Growth | -0.325 |
| Revenue Per Share | 0.442 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 64,526,242 |
| Shares Percent Shares Out | 0.1783 |
| Shares Short | 11,505,410 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 11,203,427 |
| Short Name | Stoke Therapeutics, Inc. |
| Short Percent Of Float | 0.1852 |
| Short Ratio | 12.49 |
| Source Interval | 15 |
| State | MA |
| Symbol | STOK |
| Target High Price | 60.0 |
| Target Low Price | 35.0 |
| Target Mean Price | 46.46154 |
| Target Median Price | 44.0 |
| Total Cash | 292,817,984 |
| Total Cash Per Share | 4.538 |
| Total Debt | 2,682,000 |
| Total Revenue | 27,588,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.38 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 31.359526 |
| Two Hundred Day Average Change | -8.659525 |
| Two Hundred Day Average Change Percent | -0.276137 |
| Type Disp | Equity |
| Volume | 462,285 |
| Website | https://www.stoketherapeutics.com |
| Zip | 1,730 |